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ABSTRACT
Amyloid plaques mostly comprised of variants of the A3 protein are hallmarks of the AD brain,
and the C-terminus of AP has been identified as an important region for determination of the rate of
aggregation of the peptide into fibrils. SSNMR and FTIR studies have suggested an internal
framework of hydrogen bonds and hydrophobic interactions which can stabilize the A3 fibril and
increase the favorability of fibril formation. Replacements of amide bonds in the peptide backbone
with esters were synthesized and examined to determine these effects. We present evidence that
disruption of the polyamide hydrogen-bond network can alter the kinetic and structural
characteristics of the 0(34-42) fibril.
Congo red has been used as a stain for amyloid deposits in Alzheimer's disease for the past five
decades. Two compounds, based on the core molecule Congo red and a bipyridine-technetium
ligand, were designed as possible A3 imaging and diagnostic targets. Both are also possible first-
generation A3 fibrillization inhibitors. Further ideas for a next generation of amyloid inhibitors,
based on modifications of functional groups, are also discussed.
Thesis Supervisor: Peter T. Lansbury, Jr.
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Chapter I
KINETIC AND STRUCTURAL ANALYSIS OF DEPSIPEPTIDE ANALOGS OF
THE P(34-42) PEPTIDE.
Background
The brains of Alzheimer's disease (AD) victims and Down syndrome patients are characterized by
the presence of amyloid plaques, the cores of which are comprised of the 39-43 amino acid P-
amyloid protein (AP), (Figure 1) an alternative splicing product of the amyloid precursor protein. -
5 The major components of plaque are the 40- and 42-amino acid isoforms (3(1-40) and 3(1-42),
respectively).6 Both 3(1-40) and 03(1-42) have been shown to aggregate under in vitro conditions,
and aggregation is characterized by a lag time with little or no increase in fibrillar material followed
by a rapid increase in fibril growth. consistent with a nucleation-dependent mechanism. 7.8 Soluble
f3(1-42) and [(1-40) protein have also been found circulating in the cerebrospinal fluid of healthy
individuals at nanomolar concentration. 9 The amount of [(1-42) protein has been shown to be
dramatically increased in some familial and early-onset AD patients, l0 and [3 1-42) fibrils have been
shown to seed aggregation of 3(1-40). 1(1-42) has also been found to be less soluble than 3(1-
40) under in vitro conditions. 7 These results have led to suggestions that the ratio of P(1-42) to
[3(1-40) in the brain may be a critical factor in amyloid deposition. 1.6.11.12
The synthetic peptide comprising the hydrophobic C-terminus of the A3 protein. 3(34-42)
(Figure 1), readily forms amyloid fibrils and has been used as a model system for A3.'3-15 Since
amyloid-forming proteins are typically extremely insoluble and do not readily crystallize, X-ray
crystallographic studies are of limited use in probing their structure. 16 As a result. our laboratory
H2N-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-OH
H2 N-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH
Figure 1: a) the P-amyloid peptide. The predominant species in AD brain are the 42- and 40-
amino acid variants. b) the C-terminus of AD, 0(34-42).
has used both FTIR and SSNMR methods for examining the P(34-42) peptide.'15 17.18 These
studies have shown that 1(34-42) forms antiparallel 1-fibrils which can be observed by electron
microscopy.' 3 It was originally believed that there may have been a cis -peptide bond between
Gly37 and Gly38 in the fibril, however further experiments have shown this to be unlikelyl7"8s
Our model proposes hydrogen-bond contacts are made in one of two discrete patterns between
each molecule of 1(34-42) and its nearest neighbors. In addition, the hydrophobic side chains
seem to be in a close-packing arrangement, with their van der Waals' radii nearly overlapping,
excluding water from the system (see Figure 2). 17 In particular, Ile41 and Ala42 are critical to the
network, with hIe41 packed against Va139 of the same strand and Met35 of the neighboring strand,
and Ala42 surrounded by Val40 of the same strand and Leu34 of the neighboring strand. 17 These
hydrophobic interactions offset the entropic costs of trapping the 1(34-42) peptide in the amyloid
fibril. In each of these models, the polyamide backbone plays a crucial role, either by providing
hydrogen bond donors and acceptors, or by limiting the flexibility of side chains. As a result, we
became interested in how modifications to the backbone would affect the structure and mechanism
of aggregation of the 1(34-42) peptide. An understanding of the structural determinants of amyloid
aggregation would greatly benefit the search for in vivo binders of amyloid as well as inhibitors of
amyloid formation, which could be potential AD therapeutics.
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FIGURE 2: a) One possible orientation of the individual peptide strand in the
P-sheet of the fibril.' 7 b) The 3-sheet with one amide replaced by an ester. Note the
deletion of an internal hydrogen bond. This interaction would likely be replaced by a
water molecule (not shown), which would be entropically expensive. Esters shown are
LMVGGVoVIA and LMVGGVVIoA.
A I i'
Bartlett and co-workers 19 and Kent and co-workers 20 have replaced the amide backbone in
proteins with various functional groups in order to probe the role of the peptide backbone in both
structure and function. Thus, measurements of the interaction of the zinc endopeptidase
thermolysin with a substrate found a major shift in binding energy upon replacement of a
phosphoramidate with a phosphonate ester. 19 These results cannot necessarily be construed as
providing the strength of the hydrogen bond interaction, however, due to the difficulty of
separating the free energy change due to the hydrogen bond from that due to solvation, as well as
non-equivalence of the hydrogen bonds involved.21 Depsipeptides have also been shown to have
large differences in binding drugs or receptors from their peptide analogs, and several bacteria have
been shown to use modifications from amino acids to hydroxy acids, making peptides into
depsipeptides, as a method of conveying drug resistance to themselves and their progeny. For
example, resistance to vancomycin in E. faecium is conferred by the replacement of alanine by
lactic acid in a cell-wall dipeptide.22
With this in mind, we undertook an examination of the effect on aggregation of the replacement
of various amide bonds in the 1(34-42) peptide backbone with esters. Two factors originally
influenced our decision: an interest in the earlier Gly-Gly bond measurement, and an interest in
disruption of the putative hydrogen-bonding and hydrophobic packing network. The lower barrier
to rotation between the cis and trans isomers in the ester versus the amide would presumably
provide greater flexibility in the peptide backbone. Our hydrogen-bonding model also suggests
deletion of the amide hydrogen bond donor at positions near the C-terminus may disrupt some of
the stabilizing contacts predicted to exist in our model of the fibril. Finally, the greater entropic cost
of desolvation of the ester and disruption of the hydrophobic interactions stabilizing the fibril
would decrease the favorability of the aggregation pathway. Replacements at Gly37 and Va139
were expected to have an effect on aggregation due to their proximity to regions of P(34-42)
previously shown to be of interest.7 "14. 15"17 We present evidence here that ester replacement can
affect on the rate of in vitro amyloid formation, and may help to explain the transition of A3 from
soluble form to aggregate.
Materials and Methods
Synthesis and Purification of Depsipeptides. Peptides 3(34-42) and depsipeptides LMVG-
Y[CO2]-GVVIA (GoG), LMVGG-T[CO2]-VVIA (GoV), and LMV-P[CO2]-GGVVIA (VoG)
were synthesized manually on the Wang resin using standard Fmoc chemistry. The ester linkages
were prepared by coupling the corresponding hydroxy acid to the resin-bound peptide using
standard solid-phase peptide synthesis techniques, then forming the ester by addition of the next
Fmoc-amino acid (3 eqs.) with diisopropylcarbodiimide (3 eqs.) and dimethylaminopyridine (5
eqs.) and coupling on the resin for 24 h.23,24 Depsipeptides LMVGGV-T[C02]-VIA (VoV) and
LMVGGVVI-T[C02]-A (IoA) were manually synthesized on Kaiser oxime resin using Boc
protocols; 25.26 in these cases, Boc-Val-I[CO2]-Val-OH and Boc-Ile-W[C02]-Ala-OH were
synthesized according to a published procedure27 and added to the resin as a single unit. Boc-Val-
P[CO2]-Val-OH was in accordance with earlier reported literature values. 28 Peptides were cleaved
from the resin with N-hydroxypiperidine and the C-terminus converted to the free acid with zinc
and 90c> aqueous acetic acid. 15 The filtrates were concentrated, and the depsipeptides precipitated
Vo G
Go G
Go V
VoV
IoA
Rt (min.)
29.30
21.42
16.66
17.44
17.53
Gly (exp.)
1.2 (1)
1.2 (1)
1.3 (1)
2.1 (2)
2.4 (2)
Ala
1.2 (1)
1.2 (1)
1.1 (1)
1.2 (1)
N/A
Val
2.3 (2)
2.1 (3)
2.6 (2)
2.0 (2)
2.1 (3)
Met
0.7 (1)
0.8 (1)
0.7 (1)
0.6 (1)
0.7 (1)
Ile
1.1 (1)
1.0 (1)
1.0 (1)
1.0 (1)
1.1 (1)
Leu
1.6 (1)
1.7 (1)
1.7 (1)
1.1 (1)
1.8 (1)
Table 1: Retention volumes and amino acid analyses for depsipeptides VoG, GoG, GoV, VoV,
and IoA (amino acid analysis based on leucine).
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by the dropwise addition of cold H20. Precipitates were collected by centrifugation, washed with
water and lyophilized. Peptides were dissolved in HFIP and purified by RP-HPLC on a C4
column (5 min. 90% water with 0.1% TFA/10% 5:95 trifluoroethanol:acetonitrile, 5 min gradient
to 80:20, 20 min gradient to 70:30, see Table I for retention volumes). Peptides were analyzed by
PD-MS or FAB-MS (Quality Controlled Biochemicals). Purity was greater than 90% as judged by
analytical RP-HPLC (85% water with 0.1% TFA/15% 5:95 trifluoroethanol:acetonitrile). Mass
spectrometry: P(34-42): 876.2, 860.3(M+); VoG: 875.3, 860.1(M+), 811.0, 786.0; GoG: 876.2,
860.1(M+), 814.8, 784.9; GoV: 874.0, 859.3(M+), 830.8, 600.2; VoV: 859.8(M+); IoA:
859.9(M+).
Boc-L-isoleucyl-L-ax-lactic acid benzyl ester. To a solution of L-a-lactic acid benzyl
ester (7.58 g, .042 mol), dimethylaminopyridine (.531 g, 4.35 mmol) and Boc-L-isoleucine-OH
(12.16 g, .051 mol) in dichloromethane (40 ml) was added diisopropylcarbodiimide (6.58 ml,
.042 mol). The solution was allowed to stir for 4 hours at RT, the urea precipitate filtered off and
the solvent removed in vacuo to yield a yellow-white gum. The residue was chromatographed on
silica gel (8:92 ethyl acetate:hexane) to afford the product, Boc-L-isoleucyl-L-o-lactic acid benzyl
ester (10.82 g, 65%). 1H NMR(300 MHz, CDC13): 8 7.36 (s, 5 H), 5.19 (dd, 1 H, J 1 = 7.2 Hz,
J2 = 5.7 Hz), 5.18 (s, 2 H), 5.12 (d, 1 H, J = 5.7 Hz), 4.36 (q, 1 H, J = 4.2 Hz), 1.54 (d, 3 H, J
= 6.6 Hz), 1.47 (s, 9 H), 1.20 (m, 1 H), 0.99-0.89 (m, 8 H); 13 C NMR(300 MHz, CDC13): 6
171.82 (Boc C=O), 170.17 (COOBn), 155.54 (int. C=O), 128.55, 128.46, 128.39, 128.17
(phenyl), 79.72 (C t-butyl). 69.10 (O-CH), 66.96 (O-CH2), 57.64 (N-CH), 37.85 (isoleucyl
CH), 28.25 (t-butyl), 24.52 (CH-CH2), 16.92 (lactyl CH3), 15.21 (CH3-CH), 11.56 (CH3-
CH2).
Boc-L-isoleucyl-L-a(-lactic acid. Boc-L-isoleucyl-L-a-lactic acid benzyl ester (10.79 g,
.027 mol) was dissolved in methanol and hydrogenated in the presence of 10% Pd/C for 4.5
hours. The resultant solution was filtered through Celite, and concentrated to the product, Boc-L-
isoleucyl-L-ao-lactic acid, as a white solid (4.666 g, 56%). 1H NMR(300 MHz, CDC13): 6 6.32
(d, 1 H, J = 6.8 Hz), 5.12 (m, 2 H), 4.31 (dd, 1 H, J = 4.3 Hz, J2 = 8.8 Hz), 4.09 (m, 1 H),
1.52 (d, 3 H. J = 8.8 Hz), 1.42 (s, 9 H), 1.15 (m, 2 H), 0.96 (d, 3 H, J = 7.0 Hz). 0.89 (t, 3 H,
J = 7.3 Hz); 13 C NMR(300 MHz, CDC13): 8 175.34 (Boc C=O), 171.97 (COOH), 155.90 (int.
C=O), 80.11 C t-butyl), 68.78(O-CH), 57.84 (N-CH), 37.85 (isoleucyl CH), 28.34 (t-butyl),
24.49 (CH-CH2), 16.92 (lactyl CH3), 15.41 (CH3-CH), 11.65 (CH3-CH2).
Electron Microscopy. Depsipeptides aggregated as described above were suspended on carbon-
coated copper grids and stained with 2% (w/v) uranyl acetate. Pictures were taken using a JEOL
100-S electron microscope at 80 kV.
FTIR Spectroscopy. Suspensions of amyloid fibrils formed as described above were
centrifuged to remove DMSO and buffer, washed and resuspended in water, then dried on a CaF2
plate. Spectra were recorded on a Perkin-Elmer 1600 series FTIR spectrophotometer. For each
sample a 64-scan interferogram was accumulated and averaged, and the contribution from air
subtracted.
Kinetic A gregation Studies. Stock solutions were prepared by dissolving peptide in DMSO.
and the concentration determined by amino acid analysis (MIT Biopolymers Laboratory, see Table
1). Solutions toypically 10-15 mM in peptide) were vacuum frozen and thawed under argon to
minimize oxidation of methionine. Due to the tendency of the peptides to aggregate in DMSO after
2-3 weeks in solution, all stocks were used immediately upon preparation.29 Aliquots of stock
solution were added to an aqueous buffer (100 mM NaC1, 10 mM NaH2PO4, pH 7.4), and the
turbidity at 4(s) nm was measured on a Hewlett-Packard 8452a UV spectrophotometer, with scans
taken every 195.1 seconds. In order to minimize the effect of DMSO on the solubility of the
Figure 3 (facing page): EM photographs of (from top. left to right): a) 3(34-42), b)
LMVoGGVVIA, c) LMVGoGVVIA, d) LMVGGoVVIA, e) LMVGGVVIoA. Periodic higher
deposition of staining shows the fibril twist in scans cl and e). Photos shown are representative
images from .. number of scans. The scale for all scans is 100 nm.
m
peptide, the stock solution was limited to less than 10% of the final volume. Fibrils were
suspended by stirring the solution at 1440 rpm between measurements. To minimize the effects of
stirring on the light scattering measurements, stirring was stopped for 7.5 seconds before and after
each measurement. Data from two to three identical experiments were averaged to provide final
data (error in each data point = + 10%).
Solubility Measurements. Depsipeptide solutions from aggregation studies were placed in an
aqueous buffer desribed above, stirred at 1440 rpm for 24 hours, then incubated by standing at
room temperature for at least two weeks, then centrifuged at 14,000 rpm for 5 minutes and filtered
(Millipore HV 0.45 gLm filters) to remove aggregate. Concentrations were determined by amino
acid analysis as above and quantitative ninhydrin test.25
Results
Electron microscope photographs are shown in Figure 3. EM scans of depsipeptide fibrils
generally showed two types of assemblies: fibrils with a diameter of approximately 2.5 nm and
variable length, ranging from 25-100 nm, and slightly thicker twisted fibrils. 13 There were few
differences between depsipeptides and P(34-42) with the exeception of IoA, which seemed to be
composed of larger rope-like bundles of fibrils 5 nm in diameter and 70 nm in length. These
morphological differences may be responsible for the difficulty of accurately measuring the
aggregation profile of IoA (see below).
FTIRs for all depsipeptides and 3(34-42) are shown in Figure 4. In all cases, a strong peak can
be seen at - 1630 cm -l 1, indicative of the amide I stretch in a 3-sheet conformation, and a medium
peak between 1530 and 1550 cm-1 corresponds to the amide II stretch. 30.3 1 The amide I stretches
of the depsipeptides are shifted downfield by 4-6 cm-1 compared to those of P(34-42). In addition,
3(34-42) shows an additional weak stretch at 1698 cm-1, indicative of the antiparallel 3-sheet, in
accordance with earlier results. 15 None of the depsipeptides show this peak before or after
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Figure 4: Infrared scans of 13(34-4', and related depsipeptide fibrils.
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FIGURE 5: Kinetic aggregation curves of 3(34-42) and depsipeptides at 375 gtM. All runs were
performed in triplicate at 1440 rpm. Scans were taken every 195.1 seconds. Raw data was
averaged over all three runs then normalized to 100% maximum turbidity for each peptide.
Standard deviations for each peptide are represented by error bars.
• AA
deconvolution of their spectra. All depsipeptides have absorbances between 1715 and 1730 cm-
representing the ester stretch.
A comparison of kinetic aggregation data is shown in Figure 5. In general, at 375 gM,
depsipeptides showed few deviations from the aggregation profile of "native" 0(34-42). However,
at 375 pM, VoV remains soluble in buffer for at least 2 weeks, the maximum period of time light
scattering was measured. VoV does aggregate at higher concentrations (-2 mM), where lag times
are approximately 30,000 seconds. For an identical concentration of peptide, GoG was found to
reach maximum turbidity in approximately one-half the time of 3(34-42) (see Figure 1). This may
be due to an inherent flexibility in the ester bond of the GoG peptide which is not present in the
amide bond of 3(34-42), allowing it to more quickly sample the (or a) conformation necessary for
aggregation, which then traps the peptde in the fibril. Alternatively, GoG may simply possess the
necessary conformation, or a near neighbor, as its most stable form in solution. Absolute turbidity
measurements varied from peptide to peptide, as expected unless the fibrils formed from various
depsipeptides were absolutely similar.
Final solubilities of all peptides are shown in Table 2. As can be seen there is a clear trend for
solubility to increase as lag time increases, though not in a linear manner. Peptides GoG, VoG.
TABLE 2. Final Solubilities of 3(34-42) and Depsipeptides
Peptides Final Solubility (ptM)
25 + 5
28 + 8
26 + 6
76+ 16
> 1000
129 + 36
LMVGGVVIA
LMVoGGVVIA
LMVGoGVVIA
LMVGGoVVIA
LMVGGVoVIA
LMVGGVVIoA
and 3(34-42) either have no or negligible lag times, and their final solubilities are indistinguishable
from one another. These numbers cannot be considered the thermodynamic solubility of the
depsipeptides, since the analogous reverse solubilization experiments were not performed.
Previous experiments have suggested that the replacement of an amide-carbonyl interaction by
that of an ester-carbonyl has a AG of from 0.5 to 1.8 kcal/mol2' or 4.0 kcal/mol. 19 This would
imply a corresponding 1.6 to 54.5- fold increase in Ksp based solely on alteration of the amide, if
it indeed stabilizes the fibril via an amide-carbonyl interaction. Compared to 3(34-42). GoV, VoV,
and IoA all fall within this range, with VoV in particular appearing at the far end of the range,
approximately 50-fold less soluble than 3(34-42).
Earlier experiments in our laboratory7 have shown that both 3(1-42) and NAC are capable of
seeding formation of the 3(1-40) fibril. To determine if depsipeptides with an extended lag time
could interfere with the aggregation of 3(34-42), we mixed stock solutions of GoG. IoA. and VoV
with 3(34-42) stock in a 10:90 ratio, then ran the new solutions in accordance with our aggregation
protocol. In all cases, there was no discernible alteration of the 0(34-42) aggregation curve (data
not shown).
Discussion
At present, it is unknown whether aggregated A3 is made up of a single conformer or occupies a
number of energetically similar states. Experiments recently performed have suggested that the
Gly37-Gly38 amide bond is in the trans- conformation. 18 Given the preference of the ester for the
E- as opposed to Z-isomer, and previous results suggesting that the central glycine residues may
not be part of the 3-sheet, the faster aggregation of GoG may be due to simple hydrophobic effects
of an ester versus an amide. In this model. the amide proton between Gly37 and Gly38 is solvated
in the fibril as well as free in solution, thus replacement of the amide by an ester would cause no
net entropic loss. In the case of Va139, it is possible that the peptide requires relative rigidity at this
position for rapid formation of the fibril. The barrier to rotation about the C-O bond in the ester has
been calculated as - 10-15 kcal/mol, versus 20 kcal/mol for amides32-34 . Perhaps the cis-amide
conformation is necessary as a nucleator of aggregation, but is not the most stable conformer in the
fibril itself. By this model, once the seed is formed, cis/trans isomerization takes place and favors
the lower energy conformer. It is also possible that the depsipeptides may take on an entirely
different secondary and tertiary structure from the native peptide. In this case, the different lag
times for the depsipeptides with respect to P(34-42) may be a result of differences in packing
efficiency versus a standard P-sheet within the fibril.
The mixed ester experiments show no inhibitory effect or enhancement of depsipeptides on
aggregation, at least for P(34-42). Either the two peptides follow totally independent aggregation
processes in which the native and depsipeptides each form their own, homogeneous, fibrils, or the
incorporation of the slower (or faster) aggregating depsipeptides into the 0(34-42) fibril does not
appreciably affect the aggregation pathway of the native peptide.
Previous FTIR experiments in our laboratory have suggested that Va136, Val39, and Val 40 are
important residues in the model n-sheet on the basis of a frequency shift in 13 C-labeled 3(34-
42). 15 In these experiments the amide I stretch of a 13 C-labeled carbonyl and its nearest meighbors
is shifted downfield based on energy transfer within the 0-sheet.15 Ester "labelling" should
function on a similar basis, with the amide I stretch of the sheet being displaced downfield,
although by a minor amount compared to 13 C-labelling. This work confirms the expectations of
the previous model, with perturbations at these three positions having an effect on the aggregation
rate, and therefore formation of the n-sheet in the fibril. In particular, the ester between Val39 and
Val40 should have a major effect, as it disrupts two of the four critical residues, a prediction borne
out by our results. Similarly, the central glycine residues are predicted to not be a part of the 0-
sheet structure, and so perturbation should not have a negative effect on the formation of the fibril.
The depsipeptide IoA was difficult to measure. possibly due to the macroscopic properties of its
fibril. Whereas the other depsipeptides studied in this series aggregated in fibrils which could be
easily suspended for turbidity measurements, IoA tended to aggregate into "clump" fibrils which
would immediately sediment at the spin rates used. This was confirmed in the EM scans. which
showed the IoA fibril to be much thicker than those of other depsipeptides (see above). Previous
experience in our lab has shown that the turbidity assay is very sensitive to changes in the stirring
rate of the solution35 . Thus, the kinetic data for IoA may not be directly comparable to that of other
depsipeptides.
Summary
This work has shown that seemingly minor alterations in the structure of a model AB peptide
can potentially have a major effect on its rate of aggregation and final solubility by disruption of the
hydrogen-bond structure and hydrophobic interactions of the P-sheet. In addition, such changes
can also affect the structure of the fibril itself, once formed. It is still unknown exactly hovw the
individual A3 peptides come together and self-organize to form the fibril. Further work in this area
should help to elucidate the structural requirements necessary for fibrillar formation, and point the
way towards possible therapeutics aimed at slowing or reversing the aggregation process.
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Chapter II
SYNTHESIS OF A POTENTIAL 13-SHEET NUCLEATOR AND A SPIN-
LABELLED CONGO RED DERIVATIVE.
Background
One of the great difficulties of clinical research and treatment of Alzheimer's disease is the
inability to monitor the disease progress in a living being. To date, only a probable
diagnosis of AD can be made via cognitive and physical examinations; confirmation can
only be achieved upon autopsy by examination of the brain for amyloid plaque. If it were
possible to follow the time course of brain amyloid deposition in a person suffering from
AD, it would provide many answers about the time course and correlation of
neurodegenerative events in the brain.
One of the most common methods used for identifying dense (but not diffuse)
Alzheimer's amyloid plaque is staining with the dye Congo red, which induces a green
birefringence upon binding. Indeed, the classic definition of amyloid is stated in terms of
birefringent staining with Congo red. The method of binding between Congo red and AP is
unknown, but is believed to involve intercalation of the nt system of the naphthyl and
biphenyl rings with the hydrophobic side chains of the AP C-terminus. Recent work in our
lab 2.3 has involved designing and studying various analogs of Congo red and other dyes,
such as Chrysamine G, in an attempt to determine what portions of the molecule are
important for binding to amyloid. Small changes in the structure of Congo red was found
to have major effects on the binding affinity of the dye to IAPPH, a pancreatic amyloid.2
Thus, we have theorized that different dye analogs may bind the various isoforms of AP
with different selectivities, allowing the eventual design of a dye which can selectively bind
AP3(1-42) while leaving AP3(1-40) free.
Recent work by Kelley 4 ,5 and co-workers has focused on flexible "templates"
comprising peptides linked by an aromatic diacid or diamine which could be used to induce
a peptide into a 1-sheet conformation. In the 1-sheet example, these templates function by
capturing a free peptide between two complementary peptide strands with a high propensity
for 1-sheet formation. The aromatic portion of the template can serve two functions: as a
"spacer" and link to keep the two complementary strands the proper distance necessary for
interstrand hydrogen bonds to potentially form between them and the free peptide, and as a
potential metal binder for transition metals such as copper or zinc, which can then chelate
the carboxylate moiety of the free peptide strand.
Our laboratory has recently focused on the design of small molecule compounds capable
of binding technetium which show the potential for blood-brain barrier transport as
possible imaging agents for amyloid in AD brain.3 Due to the high affinity of technetium
for nitrogen. one of our earliest experiments was the replacement of the biphenyl ring in
Congo red wvith a bipyridyl, followed by chelation of the bipyridyl nitrogens with
technetium via reaction with ammonium pertechnate. Other experiments led us to create an
analog of Congo red with an aminomethyl handle for attachment of other compounds, such
as dyes and metal binders, to use Congo reds affinity for amyloid to bring other molecules
which can be measured spectroscopically into the vicinity of the amyloid fibril. As a result,
our synthetic efforts focused in two parallel directions. In one case, we used a bipyridine
diacid linked to two truncated C-terminal AP peptides as a model compound for
sequestration of Ap. The bipyridine was chosen as a spacer due to the possibility of later
introducing metals as chelating agents into the molecule. In the other, our handled Congo
red molecule was used to attach a nitroxide free radical (3-carboxy PROXYL, 11) to the
dye, thus using the Congo red analog as a potential spin label for electron spin resonance
(ESR) studies.
In sum. the goal of our synthetic efforts was twofold. In the case of peptidomimetic
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Figure 1: Congo red derivatives and bipyridine-peptide synthetic targets.
compound 5, our goal was to develop first-generation compounds capable of binding a
molecule of AP via a "trap" into the |-sheet conformation. Theoretically, this molecule
could also act as a sequestration agent for AI, by limiting the interaction of individual Ab
peptides with one another. In the case of spin-labelled Congo red analog 13, our goal was
to determine in more detail, via electron spin resonance, the method of binding between a
molecule of Congo red and the AP$ amyloid fibril.
Materials and Methods
Synthesis of a Potential /-Sheet Nucleator. Our aromatic diacid linker 4 was synthesized
via commercially available ethyl nicotinate 1 (see Scheme 1). which was converted to 2,2'-
bipyridyl-5,5'-diethyl dicarboxylate by a known procedure, 6 then hydrolyzed in
KOH/EtOH to the diacid in quantitative yield. Diacid 3 was insoluble in all solvents and
difficult to work with, so diacid chloride 4 was made via refluxing overnight in thionyl
chloride.7 This material which was used in the coupling step.
Peptides H2N-GGLMVGG-OH and H2 N-GGGLMVGG-OH were prepared by
standard Fmoc coupling techniques on Wang resin. Purification was performed on a C 18
so.
Scheme 1
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column (100% water for 5 min., then 40 min. gradient 100% water to 80:20
water:acetonitrile, retention time = 38 min.) Purified peptides were confirmed by mass
spectrometry, and test by analytical HPLC found peptides to be greater than 95% pure.
Before attempting the coupling of the peptide and bipyridyl compound, two model
compounds were created, one by forming the diamide with two moles of glycine benzyl
ester, the other by using the alanine benzyl ester. In both cases, amidation was successful
(approximately 70% yield in both cases). However, attempted condensation between 8-mer
H2 N-GGGLMVGG-OH and bipyridine diacid chloride 4 was unsuccessful, returning only
starting material and slow hydrolysis of 4 to diacid 3.
Synthesis of a Spin-Labelled Congo Red Derivative. The central piece of the Congo red
derivative was made via commercially available 4,4'-dinitro-2-biphenylamine 6. Reaction
with NaNO 2 /CuI in sulfuric acid afforded the iodinated biphenyl compound 7, which on
treatment with CuCN in refluxing DMSO gave the cyano compound 8. Simultaneous
reduction of the cvano and nitro groups to compound 10 via hydrogenation proved
impossible, giving the diamine 9 with several impurities at pressures of up to 55 psi. The
diamine was also obtained by treatment of 8 with KBH 4 /CuCI.8 Refluxing of the diamine
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NH, I CN
NO, O, 1 H MS) H, PdIC. 45 psi
ON - /-/ NO, ,/ ON/ NO, CuCN. DMSQ NO, w KBHuCI
HRO.M!r-flux. 2 Wr. KBH/CUC/
6 7
LAH. TW. reflux EtOCOCI
HN _ / NHI HM _/ _ NH, 3-Catuoxy-PRUYL
I) NaNOJHCI
I: I THF: H O
NH.
2) # /NaOAdNa.CO,
O,S 13 SO,-
with LiAlH4 in THF overnight successfully gave the triamine 10. For attachment of the
nitroxide spin label to the central core, commercially available spin label 11 was treated
with ethyl chloroformate to form the anhydride according to a literature procedure, 9 which
upon addition to a solution of the triamine formed the spin-label derivatized central core 12.
Finally, diazotization of spin label 12 by a standard procedure gave compound 13. Mass
spectrometry to date has been inconclusive for compounds 12 ad 13. giving no M+H peak
but a series of smaller peaks corresponding to a diazotized naphthyl group in 13.
Future Directions
1) P-Sheet Nucleator. After synthesis of compounds 5 and 6, obviously the next step
would be to determine if such compounds are able to affect the aggregation rate of the A3
peptide, as measured by our aggregation assay,' 0 or through the assay of Teplow.11 Since
both the 7- and 8-amino acid peptides have considerable water solubility, additional amino
--
a InIv
acids in the 13(34-42) sequence could be added to find the maximum length of the A
peptide before solubility is appreciably affected. Other hydrophobic sequences, such as
poly-valine or poly-phenylalanine, have also been suggested for their potential ability to
bind to the 0-amyloid fibril.
2) Spin-Labelled Congo Red. The Congo red assay has been developed by several
laboratories 1.12 The fibrils of the C-terminal peptide 0(34-42) have been determined by
previous work to exhibit most of the properties of full-length 1(1-42) fibrils when stained
with Congo red, and is amenable to solid-state NMR studies. 13 This shorter peptide could
be easily used for ESR studies to elucidate the structure of the bound CR-amyloid fibril,
although extrapolations of binding modes to full-length 1(1-42) may not be completely
analogous due to the absence of possible binding sites. For example, amino acids 12 to 15
have been suggested as a possible binding site for Congo red. 14 In addition, the above
synthesis lends itself easily to the derivatization of other aromatic biphenyl azo dyes. For
example, Chrysamine G, which has also been used as an amyloid stain, is easily derived
from a similar synthesis to the one outlined for Congo red, with salicylic acid replacing 4-
amino-l-naphthalene sulfonic acid in the final diazotization step (see Scheme 3). Such a
compound would conceivably give us further information regarding binding of such
molecules to amyloid fibrils.
Ongoing research in our labs has used compound 10 as the precursor for an entire
family of Congo red and Chrysamine G analogs (see Figure 2). In addition, another dye-
binder has been created using 4-hydroxy-1 -naphthalene sulfonic acid instead of 4-amino-1-
naphthalene sulfonic acid as the naphthyl portion of the dye (W. Zhen and M. Anguiano,
unpublished data). These compounds could be the first generation of a series of aromatic
dye analogs whose affinity for various amyloid fibrils, such as those predominantly
derived from AP(1-42) or AP(1-43), another variant form of long A3, could be tuned by
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Experimental
2-Iodo-4,4'-dinitrobiphenyl (7). 5,5'-Dinitro-2-biphenylamine (10.03 g, 38.7
mmol) was dissolved in concentrated H2 SO 4 (40 ml) with stirring. Separately, NaNO2
(3.52 g) was mortar ground and added in portions to H2 S0 4 (25 ml) at 50 C, with
minimum evolution of nitrogen. The resulting slush was pipetted into the amine solution at
0' C, followed by 85%c phosphoric acid (95 ml) added by addition funnel over 1 hour,
maintaining the temperature below 10' C throughout. The solution was then allowed to
warm to room temperature over 2 hours with constant stirring. Due to the viscosity of the
solution, occasional hand agitation was necessary. After 2 hours, the solution was dumped
into 500 ml of ice water and stirred until the solution was homogenous, when urea (7.53 g)
was added to destroy excess nitrous acid. Finally, a solution of KI (15.26 g) in water (100
mil) was added by pipette and the solution stirred for 15 minutes. The resulting solution
was filtered, and the solid redissolved in CH 2 C12 and extracted with aqueous sodium
bisulfite. The organ-c layer was collected, dried with MgSO 4 , concentrated and
chromatographed in 1:1 hexane:CH 2 Cl 2 to yield product 7 (11.560 g, 80.9%) .1H
NMR(300 MHz, CDCl 3 ): 8 8.83 (d, 1 H, J = 2.4 Hz), 8.35 (d, 2 H, J = 8.4 Hz), 8.30
(dd, 1 H, J 1 = 8.4 Hz, J2 = 2.4 Hz), 7.55 (d, 2 H, J = 8.4 Hz), 7.48 (d, 1 H, J = 8.4
Hz): 1-C NMR(300 MHz, CDCI3 ): 8 150.44(C-4), 148.09(C-4), 147.82(C-6),
147.50(C-1), 134.50(C-3), 129.88(C-2, C-6), 124.25(C-1), 123.58(C-3, C-5),
123.16(C-5), 96.95(C-2).
2-Cyano-4,4'-dinitrobiphenyl (8). Compound 7 (11.56 g, 31.2 mmol) and CuCN
(16.80 g. .188 mol) were placed under argon, dissolved in anhydrous DMSO (50 ml) and
refluxed at 190* C for 2 hours. The reaction mixture was poured into concentrated NH4 CI
and allowed to cool to room temperature, then filtered. The solid was redissolved in THF,
and extracted with THF:CH 2 CI2 and water. The organic phase was dried with MgSO 4,
concentrated to a beige solid, and chromatographed (20:80 THF:hexane) to give an off-
yellow solid 8 (5.97 g, 71%). 1H NMR(300 MHz, CDCI3 ): 8 8.69 (d, 1 H, J = 2.4 Hz),
8.58 (d. 1 H, J = 2.4 Hz), 8.42 (dd, 2 H, J1 = 8.4 Hz, J2 = 2.4 Hz), 7.78 (m, 3 H); 13 C
NMR(_00 MHz, CDCl3 ): 8 148.67(C-4), 148.45(C-4), 147.46(C-1), 141.85(C-1).
131.27 C-6), 129.79(C-2, C-6), 128.87(C-5), 127.64(C-3), 124.25(C-3, C-5),
115.77iCN), 112.97(C-2).
4,4'-Diamino-2-cyanobiphenyl (9): Primary route. Compound 8 (1.39 g, 5.16
mmol) was placed in MeOH and 10% Pd/C (100 mg) in EtOH (5 ml) was added. The
solution was hydrogenated in a Parr apparatus for 24 hours at 55 psi. TLC in 5:95
MeOH:CH 2 Cl2 showed complete disappearance of starting material with appearance of a
new spot at Rf = 0.4. Filtration of the solution and concentration gave a yellow-orange
product which was carried over to the next step.
4,4'-Diamino-2-cyanobiphenyl (9): Secondary route. Compound 8 (975 mg,
3.62 mmol) was placed under argon and dissolved in anhydrous MeOH (30 ml) with
sonicat:on. Anhydrous CuC1 (1.24 g, 12.53 mmol) was added followed by KBH 4 (1.54
g, 28.5" mmol) in portions. Upon addition of the borohydride, a black precipitate formed
and the solution darkened to green. The solution was allowed to stir for 1 hour, then
concentr-ated to remove MeOH. The resultant was redissolved in H2 0, filtered and the
solution extracted with EtOAc. The organic layer was dried was dried with MgSO 4 ,
concentrated to a yellow solid, and chromatographed (1:99 MeOH:CH 2 CI2 ) to give a red
solid, 9 (588 mg, 77.6%). 1H NMR(300 MHz, DMSO-d 6 ): 8 7.66-7.59 (m, 3 H), 7.37-
7.32 (m, 2 H), 7.10-7.04 (m, 2 H), 5.98 (s, 2 H), 5.69 (s, 2 H); 13 C NMR(300 MHz,
DMSO-d 6 ): 8 148.37(C-4), 147.53(C-4), 132.90(C-6), 130.39(C-6), 129.06(C-2),
126.13(C-1), 125.89(C-1), 119.90(C-5), 119.13(C-5), 117.14fC-2), 114.47(C-3),
113.87(C-3), 109.51 (CN).
4,4'-Diamino-2-(aminomethyl)biphenyl (10). In separate flasks, LiAIH 4 (369
mg, 6.255 mmol) and compound 9 (115 mg, .550 mmol) were placed under argon and
dissolved in dry THF (20 ml). The solution of 9 was added dropwise to the LAH slurry,
and the combined solutions refluxed for 19 hours at 110" C. After 19 hours, the solution
was cooled to RT, and water followed by 5% NaOH added to neutralize excess hydride.
The resultant was filtered and extracted with hexane. The aqueous layer was kept, acidified
to pH 4, extracted with CH 2Cl 2, and the resulting aqueous layer lyophilized to an orange
powder, the triamine 10 (86.8 mg, 74%). 1H NMR (300 MHz, DMSO-d 6 ): 8 6.96 (d, 2
H), 6.81 (d, 1 H), 6.73 (s, 1 H), 6.60 (d, 2 H), 6.47 (dd, 1 H), 4.94 (4 H), 3.57 (s, 2
H), 3.17 (2 H); 13 C NMR (300 MHz, DMSO-d 6 ): 8 147.06-C-4), 146.74(C-4),
130.18(C-1), 130.06(C-1), 129.84(C-2, C-6), 129.66(C-3, C-5), 129.31(C-6),
129.23(C-2), 113.72(C-3), 112.26(C-5), 67.08(CH2 ).
3-[2-(amidomethyl)-4,4-diaminobiphenyl]-2,2,5,5-tetramethy- 1-
pyrollidinyloxy, free radical (12). Spin label 3-Carboxy PROXYL (11) (93.5 mg,
.502 mmol) was dissolved in dry THF, and freshly distilled ethyl chloroformate (48 mL)
was added dropwise. The solution was stirred at room temperature for 3 hours, until TLC
(10:90 methanol:dichloromethane) confirmed consumption of starting material. A solution
of 10 (107 mg, .502 mmol) in dry THF (10 ml) was then added, and Et3 N (70 ml) finally
added dropwise. The solution was left to stir overnight, then concentrated. Chromtography
followed by mass spectrometry gave a yellow compound.believed to be 12.
3-[2-(amidomethyl)-3,3'-[4,4'-biphenylylenebis(azo)]bis[4-amino- 1-
naphthalene sulfonic acid]-2,2,5,5-tetramethyl-1-pyrollidinyloxy, free
radical (13). To an ice-cooled solution of 12 (23.9 mg, .0628 mmol) in 1:1 THF/H 20
(4 ml) was added dropwise 10% aqueous HCI (280 ml) followed by an ice-cooled solution
of NaNO 2 in H20 (64.7 mg in 280 ml). After 15 minutes at 00 C, the solution was added
dropwise to a solution of 4-amino-1-naphthalene sulfonic acid (74.5 mg, .334 mmol),
sodium acetate trihydrate (245 mg, 1.80 mmol), and sodium bicarbonate (23.9 mg, .225
mmol) in H20 (2 ml) at 00 C. The solution immediately turned red and was allowed to stir
for 1 hour. TLC (50:50 methanol:dichloromethane) showed a new spot. Material was
immediately concentrated, redissolved, and column chromatography (dichloromethane,
then 10:90 to 50:50 methanol:dichloromethane) gave a red solid believed to be compound
13 (15%). Mass spec(FAB-, glycerol matrix):m/z = 205, 221, 222, 243, 249, 265, 275,
281, 357.
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Appendix
NMR (300 MHz, DMSO or CDCI3 ):
Boc-L-isoleucyl-L-a-lactic acid benzyl ester (1H)
Boc-L-isoleucyl-L-a-lactic acid benzyl ester (13C)
Boc-L-isoleucyl-L-a-lactic acid (1H)
Boc-L-isoleucyl-L-ca-lactic acid (13 C)
2-Iodo-4,4-Dinitrobiphenyl (1 H)
2-Iodo-4,4-Dinitrobiphenyl (13C)
2-Cyano-4,4-Dinitrobiphenyl (1H)
2-Cyano-4,4-Dinitrobiphenyl (13 C)
4,4-Diamino-2-Cyanobiphenyl (1 H)
4,4-Diamino-2-Cyanobiphenyl (13 C)
4,4-Diamino-2-(aminomethyl)biphenyl (1H)
4,4-Diamino-2-(aminomethyl)biphenyl (13 C)
Mass Spectrometry
3-[2-(amidomethyl)-3,3'-[4,4'-biphenylylene
bis(azo)]bis[4-amino- 1-naphthalene sulfonic acid]-
2,2,5,5-tetramethyl-1-pyrollidinyloxy, free radical
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[ Mass Spectrum I
Data : ng001HIM
Sample: CLM-275
Note : neg ion Glycerol
Inlet : Direct
Spectrum Type : Regular [MF-Li
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